Previous 10 | Next 10 |
HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today the activation of clinical sites and initiation of enrollme...
Pluristem Therapeutics (NASDAQ: PSTI ) is selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority. More news on: Pluristem Therapeutics Inc., Healthcare stocks news, Read more ...
Collaboration will enable Pluristem to develop new technologies relying on its PLX platform The consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program, and includes industry and academic leaders in AI and genome editing ...
The following slide deck was published by Pluristem Therapeutics Inc. in conjunction with this Read more ...
Medical science has proven time and again that when the resources are provided, great progress in the treatment, cure, and prevention of disease can occur. - Michael J Fox It makes sense right now to have exposure to biotech stocks, especially companies working on COVID-19 treatments. Over...
Applied DNA Sciences (NASDAQ: APDN ) +71% after receiving FDA emergency use authorization for COVID-19 test. More news on: Applied DNA Sciences, Inc., AIM ImmunoTech Inc., Immunic, Inc., Stocks on the move, , Read more ...
Pluristem Therapeutics (NASDAQ: PSTI ) provides an update on the status of COVID-19 infected patients treated with PLX cells. More news on: Pluristem Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...
87.5% survival rate of patients on invasive mechanical ventilation injected with PLX cells 75% of patients no longer in need of any mechanical ventilation 62.5 % of the patients discharged alive from the hospital A 28-day study period is also the primary endpoint timeline...
RedHill’s COVID 19 Study Receives the FDA Go Ahead RedHill Biopharma Ltd. ( RDHL ) announced that the FDA has approved its plan for starting a mid-stage study for testing out COVID 19 drug candidate. The company’s Investigational New Drug ( IND ) application for a Phase 2a...
PAR Technology (NYSE: PAR ) +37% on Q1 results . More news on: PAR Technology Corporation, Penn Virginia Corporation, Camping World Holdings, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...